Core Insights - Ligand Pharmaceuticals' CLO Andrew Reardon exercised 5,000 stock options and sold the shares for approximately $1.03 million, indicating a strategic liquidity move rather than a reduction in long-held shares [1][9]. Transaction Summary - The transaction involved the sale of 5,000 shares at a value of $1.0 million, with post-transaction direct ownership of 36,869 shares valued at approximately $7.70 million [2]. - The sale price was based on a weighted average purchase price of $206.35 per share, reflecting the market close on March 4, 2026 [2]. Historical Context - The recent sale is significantly larger than Reardon's median sell transaction of 750 shares, which typically represented 1.73% of his holdings during the recent period [6]. - The transaction was executed under a pre-planned 10b5-1 arrangement, indicating it was scheduled prior to execution [10]. Company Overview - As of March 4, 2026, Ligand Pharmaceuticals had a market capitalization of $3.8 billion and reported a revenue of $268.09 million for the trailing twelve months [4]. - The company's stock experienced a 1-year price change of 81.6%, reflecting strong market performance [4]. Business Model and Portfolio - Ligand Pharmaceuticals operates as a biopharmaceutical innovator with a focus on technology licensing and royalty streams, targeting oncology, infectious diseases, autoimmune disorders, and rare conditions [7][8]. - The company generates revenue primarily through licensing agreements, royalties, and material sales, leveraging partnerships with pharmaceutical firms [7][8]. Future Outlook - Ligand is guiding for $200–$225 million in royalty revenue for 2026, indicating continued growth potential [10]. - Reardon retains 54,444 employee stock options, preserving his ability to increase equity participation in the company [3][10].

Company Overview - Ligand Pharmaceuticals is a biotechnology company focused on drug discovery and commercialization, leveraging a diversified portfolio of royalty-generating assets and partnerships with major pharmaceutical firms [5] - The company reported total revenue of $268.09 million and a net income of $124.45 million for the trailing twelve months (TTM) [4] Recent Transaction - On March 11, 2026, CFO Octavio Espinoza sold 3,057 shares of common stock for approximately $688,000, with a weighted average sale price of $225.00 per share [1][2] - This sale accounted for 12.70% of Espinoza's direct common stock ownership, leaving him with 21,010 shares valued at approximately $4.65 million post-transaction [6] Financial Performance - Ligand experienced significant growth in 2025, with total revenue increasing to $268.1 million from $167.1 million the previous year, driven by a 48% rise in royalty revenue to $161.0 million [9] - The company reported a GAAP net income of $124.5 million, a substantial recovery from a $4 million loss in the prior year [9] - Management forecasts revenue of up to $285 million and adjusted EPS of as much as $9.00 for 2026 [9] Business Model - Ligand operates a technology-driven partnership model, acquiring and developing pharmaceutical assets and licensing them to commercial partners, generating ongoing royalties and licensing fees [7] - The primary customers are global pharmaceutical companies and biotechnology firms seeking access to proprietary drug development technologies and commercial-stage products [7] Investor Insights - The recent insider sale appears to be a structured liquidity event rather than a negative signal for the company's fundamentals, as it was executed under a prearranged 10b5-1 plan [8] - For long-term investors, the focus should be on Ligand's ability to continue finding high-quality royalty assets to sustain growth [10]

Core Viewpoint - The article discusses the potential resilience of CVS Health and Gilead Sciences during economic downturns, suggesting they are solid investments even in uncertain economic conditions [1]. Group 1: CVS Health - CVS Health operates over 9,000 locations in the U.S. and has established strong community relationships, which may help it navigate economic challenges [2]. - The company has faced challenges in its Medicare Advantage business but is focusing on profitable growth by scaling back this segment, which should improve margins and financial results [3]. - CVS Health offers an attractive dividend yield of 3.4%, significantly higher than the S&P 500's 1.2%, and has increased its dividend by 56.5% over the past decade, making it a solid choice for recession-resistant investment [3]. Group 2: Gilead Sciences - Gilead Sciences is a leading biotech company known for its strong portfolio in the HIV market, including key products like Biktarvy and Descovy, and has expanded into oncology and COVID-19 treatments [4]. - The company's HIV products are essential for patients, which should help maintain sales even during a recession, despite recent fluctuations in revenue from Veklury [5]. - Gilead has a robust pipeline in oncology that is expected to support future product launches and sales growth, positioning the company well for economic challenges [5].

Group 1 - Gilead Sciences announced the acquisition of Arcellx, Inc. for up to $7.8 billion, paying $115 per share, which represents a 79% premium over Arcellx's last closing price [2] - Following the announcement, Arcellx's stock price surged by 77.9% to $114.06 in morning trading [2] - This acquisition is Gilead's largest since its $21 billion purchase of Immunomedics in 2020, as the company seeks to diversify beyond its traditional HIV and liver disease therapies [2][3] Group 2 - The acquisition enhances Gilead's position in cell therapy, particularly with an investigational CAR-T treatment for multiple myeloma, which is under FDA consideration as a fourth-line treatment [3] - Gilead expects the transaction to be finalized in the second quarter of 2026 [3] - Analysts suggest that the new treatment may have a better safety profile compared to existing therapies, indicating potential competitive advantages in the market [3]

Core Viewpoint - Gilead Sciences is set to acquire Arcellx for up to $7.8 billion, marking its largest deal since 2020, aimed at enhancing its cancer treatment portfolio [1] Group 1: Acquisition Details - Gilead will pay $115 per share in cash, representing a 79% premium over Arcellx's last closing price [1] - The total acquisition cost could reach $7.8 billion, which includes an additional $5 per share contingent on achieving $6 billion in cumulative global net sales of anito-cel by the end of 2029 [1] Group 2: Strategic Rationale - The acquisition is part of Gilead's strategy to diversify its offerings beyond its core HIV and liver disease treatments, especially as it faces declining sales from its COVID-19 drug Veklury and impending patent expirations [1] - Gilead's CEO highlighted that anito-cel could become a foundational treatment for multiple myeloma, with potential for earlier lines of therapy [1] Group 3: Product and Market Impact - Anito-cel, an experimental CAR-T therapy for multiple myeloma, is currently under FDA review, with a decision expected by December 23, 2023 [1] - The acquisition is anticipated to be accretive to Gilead's earnings per share starting in 2028, contingent on FDA approval of anito-cel [1]

Core Viewpoint - Gilead Sciences, Inc. reported strong fourth-quarter results for 2025, with adjusted earnings per share (EPS) of $1.86, exceeding estimates, while total revenues of $7.9 billion also surpassed expectations, driven by growth in HIV and Liver Disease drugs [1][4][6]. Financial Performance - Adjusted EPS for Q4 2025 was $1.86, beating the Zacks Consensus Estimate of $1.83, but down from $1.90 a year ago due to higher acquired IPR&D expenses [1][6]. - Total revenues reached $7.9 billion, a 5% increase year over year, surpassing the Zacks Consensus Estimate of $7.6 billion [1][4]. - Product sales increased by 5% year over year to $7.9 billion, with HIV product sales growing 6% to $5.8 billion [4][5]. Product Sales Breakdown - Biktarvy sales rose 5% year over year to $4 billion, capturing over 52% of the U.S. HIV treatment market [5][6]. - Descovy sales surged 33% year over year to $819 million, driven by increased demand for HIV prevention [6][7]. - Liver Disease portfolio sales increased 17% to $844 million, exceeding estimates, primarily due to demand for Livdelzi [8]. - Veklury sales fell 37% to $212 million, attributed to lower COVID-19 hospitalization rates [8]. Cost and Expenses - Adjusted product gross margin was 86.8%, slightly up from 86.7% year over year [11]. - Research and development expenses remained flat at $1.6 billion, while SG&A expenses decreased to $1.7 billion from $1.9 billion [11][12]. 2025 and 2026 Guidance - For 2025, revenues rose 2% year over year to $29.4 billion, exceeding estimates, with adjusted EPS increasing to $8.15 from $4.62 in 2024 [13]. - Gilead expects 2026 product sales between $29.6 billion and $30 billion, with adjusted EPS projected in the range of $8.45-$8.85 [14][15]. Pipeline and Regulatory Updates - Positive phase III results for the investigational regimen of bictegravir and lenacapavir were reported, with a potential launch targeted for the second half of the year [16][23]. - Gilead has discontinued several studies based on recommendations from independent committees, including the phase III STAR-221 study [18][19]. Market Position and Competitive Landscape - Gilead's HIV business exceeded management's growth target, driven by strong performances from Biktarvy and Descovy, despite competitive pressures [21][22]. - The company anticipates continued competitive pressures in cell therapies and expects to face headwinds from U.S. government drug pricing agreements [24][27].

Core Viewpoint - Gilead expects its HIV portfolio sales to grow by 6% in 2026, driven by the recently launched PrEP drug Yeztugo, despite facing some headwinds from regulatory agreements and market conditions [1][2][6] Sales Performance - Gilead's HIV drugs generated $20.8 billion in sales for the full year 2025, marking a 6% increase from 2024, primarily due to the strong performance of Biktarvy, which saw sales rise by 7% to $14.3 billion [1][4] - The company anticipates total product sales between $29.6 billion and $30 billion in 2026, factoring in a decline in demand for Veklury, a Covid-19 antiviral [5] Yeztugo's Impact - Yeztugo, a biannual PrEP option, achieved $150 million in sales in 2025 after its FDA approval in June, with expectations to reach $800 million in 2026, representing a 433% year-over-year growth [3][6] - Analysts from Citi believe that the sales target for Yeztugo is achievable, indicating strong market potential [3] Future Projections - GlobalData forecasts that Yeztugo will continue to grow, potentially reaching $5.34 billion in annual sales by 2031, supported by ongoing demand for HIV prevention [4] - Gilead's CEO emphasized the company's secure business outlook, with no major loss of exclusivities until 2036, suggesting a stable growth trajectory [6]

Core Insights - Gilead Sciences reported $7.93 billion in revenue for Q4 2025, a year-over-year increase of 4.7% and a surprise of +4.63% over the Zacks Consensus Estimate of $7.57 billion [1] - The EPS for the same period was $1.86, slightly down from $1.90 a year ago, with an EPS surprise of +1.91% compared to the consensus estimate of $1.83 [1] Financial Performance - Total product sales in the U.S. reached $5.87 billion, exceeding the average estimate of $5.59 billion, representing a year-over-year change of +5.8% [4] - Total product sales globally were reported at $7.9 billion, surpassing the six-analyst average estimate of $7.53 billion, with a year-over-year change of +4.9% [4] - Royalty contract and other revenues were $22 million, below the average estimate of $38.66 million, reflecting a year-over-year decline of -33.3% [4] Product Sales Breakdown - Product sales for Liver Disease (Other) in the U.S. were $168 million, significantly above the average estimate of $141.36 million, marking a year-over-year increase of +189.7% [4] - Sales for HIV product Biktarvy totaled $3.97 billion, exceeding the average estimate of $3.79 billion, with a year-over-year change of +5.1% [4] - Sales for Veklury were $212 million, below the average estimate of $266.85 million, indicating a year-over-year decline of -37.1% [4] Stock Performance - Gilead's shares have returned +23.7% over the past month, while the Zacks S&P 500 composite showed no change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Gilead Sciences reported a strong performance in its HIV segment, with full-year sales reaching $20.8 billion, a 6% increase year-over-year, and fourth-quarter sales hitting a record $5.8 billion, also up 6% [1][6]. Financial Performance - Total product sales for the fourth quarter were $7.9 billion, a 5% increase year-over-year, while excluding Veklury, sales were $7.7 billion, up 7% [2]. - For the full year 2025, Gilead's total product sales were $28.9 billion, up 1% from 2024, exceeding guidance [3]. - The base business sales, excluding Veklury, were $28.0 billion, up 4% year-over-year, and would have been 8% without the impact of the Medicare Part D redesign [2][6]. HIV Business Highlights - The HIV business faced a $900 million headwind from the Part D redesign in 2025, but management indicated that excluding this impact, HIV sales grew by 10% [1]. - Biktarvy, a key treatment, generated fourth-quarter sales of $4.0 billion, up 5% year-over-year, and full-year sales of $14.3 billion, up 7% [7]. - The injectable HIV prevention product Sunlenca generated $150 million in 2025, with management forecasting about $800 million in revenue for 2026 [8][9]. Liver and Oncology Performance - Gilead's liver disease business grew 6% in 2025 to $3.2 billion, with fourth-quarter sales of $844 million, up 17% year-over-year, driven by the adoption of Livdelzi [12]. - In oncology, Trodelvy sales rose 6% in 2025 to $1.4 billion, with fourth-quarter sales of $384 million, up 8% year-over-year [13]. Future Guidance and Pipeline - For 2026, Gilead expects total product sales of $29.6 billion to $30.0 billion, with base business sales projected to grow 4% to 5% [21]. - The company plans multiple potential launches in 2026, including Trodelvy for first-line TNBC and a combination therapy for HIV [5][18]. - Management anticipates a product gross margin of about 87% and non-GAAP diluted EPS of $8.45 to $8.85 for 2026 [22]. Capital Return Strategy - Gilead returned $5.9 billion to shareholders in 2025, including $1.9 billion in share repurchases, and aims to return at least 50% of free cash flow to shareholders [24].

Q425 & FY25 Financial Results 1 0 D e c e m b e r 2 0 2 4 F e b r u a r y 1 0 , 2 0 2 6 Forward-Looking Statements Statements included in this document that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilea ...